<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Human immunodeficiency virus and dialysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Human immunodeficiency virus and dialysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Human immunodeficiency virus and dialysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christina M Wyatt, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Molly Fisher, DO, FASN
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul E Klotman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steve J Schwab, MD, FACP, FASN
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney disease is an important complication of human immunodeficiency virus (HIV) infection, particularly in individuals of African descent [
         <a href="#rid1">
          1
         </a>
         ]. A collapsing form of focal segmental glomerulosclerosis (FSGS) with associated tubular microcysts and interstitial inflammation is the classic form of HIV-related kidney disease, known as HIV-associated nephropathy (HIVAN). HIV infection has also been associated with other forms of kidney disease, in particular, immune complex disease [
         <a href="#rid2">
          2
         </a>
         ]. With prolonged survival and aging of the population, people living with HIV (PWH) are also at increased risk for chronic kidney disease (CKD) due to comorbid conditions, such as diabetes and hypertension.
        </p>
        <p>
         Some of these kidney diseases can result in end-stage kidney disease (ESKD). Issues relating to HIV and dialysis will be reviewed here. HIV-related disorders of the kidney are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with the general population, people living with HIV (PWH) are at increased risk for end-stage kidney disease (ESKD). In a population-based cohort study from Denmark, PWH had a fourfold higher risk of ESKD compared with age- and sex-matched controls [
         <a href="#rid3">
          3
         </a>
         ]. Data from the United States Veterans Affairs (VA) health care system have demonstrated that the risk of ESKD is associated with both HIV-related factors (high HIV-RNA, low CD4, and hepatitis C virus coinfection) and traditional kidney disease risk factors (diabetes, hypertension, and cardiovascular disease) [
         <a href="#rid4">
          4
         </a>
         ]. A subsequent study from the VA suggests that ESKD may occur at a younger age in veterans living with HIV versus those not living with HIV, although the difference is small [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Both HIV-related factors and traditional kidney disease risk factors were also associated with a combined endpoint of ESKD and advanced chronic kidney disease (CKD) in two large HIV cohort studies, D:A:D and EuroSIDA [
         <a href="#rid6">
          6,7
         </a>
         ]. In a smaller, retrospective cohort study from Germany, injection drug use and being Black were the only independent risk factors for ESKD in PWH [
         <a href="#rid8">
          8
         </a>
         ]. Over the 20-year study period, these authors observed a decline in the prevalence of ESKD among Black PWH and an increase in the prevalence of ESKD among White PWH, although the racial disparity in ESKD risk remained significant.
        </p>
        <p>
         Data from the VA health care system and from the Johns Hopkins HIV cohort have also demonstrated a striking disparity in the risk of ESKD among Black PWH, who may have as much as a 30-fold increase in the risk of ESKD compared with White PWH [
         <a href="#rid9">
          9-11
         </a>
         ]. In the VA cohort, the risk of ESKD among Black PWH was similar to that observed among patients with diabetes [
         <a href="#rid9">
          9
         </a>
         ]. Genetic variability in the apolipoprotein L1 (
         <em>
          APOL1
         </em>
         ) gene on chromosome 22 appears to account for a significant proportion of the racial disparity in ESKD risk [
         <a href="#rid12">
          12
         </a>
         ], including the risk of HIV-associated nephropathy (HIVAN) and other forms of focal segmental glomerulosclerosis (FSGS) [
         <a href="#rid13">
          13-15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes", section on 'FSGS in Black patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349301625">
         <span class="h2">
          Prevalence of human immunodeficiency virus infection in the dialysis population
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of HIV infection in patients on chronic dialysis has not been well described, but available data suggest that it varies based on the prevalence of HIV infection in the local community.
        </p>
        <p>
         Nationally representative data on the United States ESKD population are collected by the United States Renal Data System (USRDS). Unfortunately, the Health Care Financing Administration (HCFA) 2728 form, which is used to collect data for the USRDS, no longer collects data on HIV status, unless ESKD is attributed to HIVAN (documented as "AIDS nephropathy" on the 2728 form). As a result, the USRDS no longer provides nationally representative data on the prevalence of HIV infection in the United States dialysis population.
        </p>
        <p>
         A 2017 analysis of administrative and clinical data from a large United States dialysis provider identified 7211 prevalent PWH among a total dialysis population of 417,756 (1.7 percent) [
         <a href="#rid16">
          16
         </a>
         ]. PWH on chronic dialysis were more likely to be Black and less likely to have ESKD attributed to diabetic kidney disease compared with patients without HIV. There were no clinically significant differences in dialysis modality, although peritoneal dialysis was less common in patients coinfected with HIV and hepatitis C virus.
        </p>
        <p>
         Although the widespread dissemination of antiretroviral therapy (ART) substantially reduced the incidence of ESKD attributed to HIVAN [
         <a href="#rid17">
          17
         </a>
         ], the true frequency of HIVAN in the ESKD population is difficult to determine, as definitive diagnosis requires kidney biopsy. (See
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          HUMAN IMMUNODEFICIENCY VIRUS TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend voluntary, confidential HIV testing of all patients on chronic dialysis. This recommendation is consistent with recommendations from the United States Preventive Services Task Force to screen all individuals age 15 to 65 years for HIV infection [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Potential clinical benefits of routine screening include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved patient survival with the use of antiretroviral therapy (ART), regardless of CD4 cell count (see
         <a class="local">
          'Antiretroviral therapy'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential to reverse HIV-associated nephropathy (HIVAN) with the initiation of ART [
         <a href="#rid19">
          19,20
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Implementation of measures to prevent transmission to partners, including initiation of ART in the patient and consideration of preexposure prophylaxis in HIV-negative partners (see
         <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">
          "HIV infection: Risk factors and prevention strategies"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          False-positive results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with low-risk patient populations without end-stage kidney disease (ESKD), conventional HIV testing by enzyme immunosorbent assay (EIA) with confirmatory Western blot in patients with ESKD has been associated with an increased incidence of false-positive EIA and indeterminate Western blot results [
         <a href="#rid21">
          21-25
         </a>
         ].
        </p>
        <p>
         False-positive and indeterminate results are thought to result from the presence of cross-reacting antibodies against CD4+ T lymphocytes or against viral antigens [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Recommendations for HIV screening and confirmatory testing are discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3743.html" rel="external">
          "Techniques and interpretation of HIV-1 RNA quantitation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TRANSMISSION IN THE DIALYSIS UNIT
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV transmission in the dialysis setting, which is rare, can be avoided by strict adherence to standard infection-control procedures [
         <a href="#rid26">
          26
         </a>
         ]. Transmission of the hepatitis B virus poses a much greater risk.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Dialysis isolation
         </span>
         <span class="headingEndMark">
          —
         </span>
         As long as health care workers follow standard dialysis unit precautions, no special isolation of people living with HIV (PWH) on dialysis is necessary. The Centers for Disease Control and Prevention (CDC) does not recommend routine isolation or dedicated machines for PWH undergoing hemodialysis, given the low likelihood of patient-to-patient and/or patient-to-staff transmission [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Patient-to-patient transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, patient-to-patient transmission of HIV infection has not been reported in a dialysis unit [
         <a href="#rid28">
          28
         </a>
         ]. However, at least four well-documented outbreaks of patient-to-patient HIV transmission have occurred in hemodialysis units outside of the United States, including Argentina (two centers), Colombia, and Egypt [
         <a href="#rid29">
          29-31
         </a>
         ]. Seroconversion was documented in 9 of 13 patients in the Colombian unit and 24 of 39 patients in the Egyptian center. When compared with HIV-positive local controls, nucleotide sequence analyses in nearly half of these cases were consistent with a common source of exposure.
        </p>
        <p>
         The most likely causes of transmission were breaches in infection-control protocol; however, no single activity could be implicated. Possibilities included reuse of the dialyzer, blood lines, and needles for different patients; the use of a weak chemical germicide (benzalkonium chloride) to reprocess needles; contamination of the ports connecting the dialysis machine to the blood lines; and the use of a contaminated multidose heparin vial.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Needlestick transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of HIV seroconversion after a needlestick injury is estimated to be 3 in 1000 or 0.3 percent. By comparison, the estimated risk of transmission after a similar event is 6 to 30 percent and 2 percent for hepatitis B and C virus, respectively [
         <a href="#rid32">
          32
         </a>
         ]. The larger the blood inoculum, the deeper the percutaneous injury, and the later the stage of HIV infection in the source patient, the greater the risk of HIV transmission [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Postexposure prophylaxis with antiretroviral therapy (ART) should be offered to exposed health care workers or care partners of patients on home hemodialysis. (See
         <a class="medical medical_review" href="/z/d/html/3764.html" rel="external">
          "Management of health care personnel exposed to HIV"
         </a>
         .)
        </p>
        <p>
         Education of all health care workers, staff, trainees, and care partners in standard infection-control procedures and needlestick protocols is essential. Although rare, documented patient-to-patient and patient-to-health care worker HIV transmission in the dialysis environment makes routine HIV screening valuable in detecting outbreaks and assisting in the decision to initiate postexposure prophylaxis. Adherence to dialysis unit precautions should minimize the risk of HIV transmission.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Viral levels in ultrafiltrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a paucity of evidence relating to the presence or absence of HIV in hemodialysis ultrafiltrate. In one study of 10 ART-treated patients, slightly lower levels of virus were detected in blood post-hemodialysis as compared with predialysis levels [
         <a href="#rid34">
          34
         </a>
         ]; however, no viral RNA was detectable in the ultrafiltrate. The authors hypothesized that the absence of HIV in the ultrafiltrate could be explained by viral adherence to the dialysis membrane.
        </p>
        <p>
         HIV virus that is capable of replication is recoverable from peritoneal dialysis effluent [
         <a href="#rid35">
          35-37
         </a>
         ]. One study found that HIV was recoverable at room temperature for up to seven days in peritoneal dialysis drainage bags and up to 48 hours from dry tubing [
         <a href="#rid37">
          37
         </a>
         ]. No difference in viral recovery was demonstrated between 1.5, 2.5, and 4.25 percent dextrose solutions. Because survival of replication-competent HIV requires an intracellular environment, the presence of peritonitis may increase the duration of HIV viability within peritoneal dialysis effluent.
        </p>
        <p>
         The clinical significance of replication-competent HIV in the peritoneal dialysis effluent is unknown. Although no case of HIV transmission via peritoneal dialysis effluent has been described, the fluid poses a theoretical biological risk to disposal workers and medical personnel. Dilutions to 1:512 of both 10 percent bleach and 50 percent
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         (Amukin) are effective in preventing HIV recoverability in vitro [
         <a href="#rid37">
          37
         </a>
         ], while household bleach is too dilute to serve as a disinfectant.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          ISSUES RELATED TO DIALYSIS MODALITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no strong evidence to suggest that one dialysis modality is superior, and both hemodialysis and peritoneal dialysis should be considered in people living with HIV (PWH) approaching end-stage kidney disease (ESKD) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         There are several issues unique to the specific dialysis modality utilized among PWH. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodialysis access infections and complications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dialyzer reuse
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peritonitis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Hemodialysis access infections and complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early arteriovenous fistula (AVF) creation is recommended in all PWH who are approaching ESKD and who plan to use hemodialysis [
         <a href="#rid39">
          39
         </a>
         ]. When an AVF is not technically feasible, we advocate creation of an arteriovenous graft (AVG) rather than a tunneled, cuffed catheter since the latter confers an even higher infection rate regardless of HIV status.
        </p>
        <p>
         Retrospective studies, largely from the era prior to effective antiretroviral therapy (ART), reported a significant increase in AVG infections and thrombosis in PWH. However, more recent data suggest that PWH undergoing arteriovenous access creation have similar outcomes to patients without HIV [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Dialyzer reuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Centers for Disease Control and Prevention (CDC) recommends that the care of PWH on hemodialysis include routine dialysis unit precautions, with optional reuse of the dialyzer by the same patient [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1863.html" rel="external">
          "Reuse of dialyzers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Peritonitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In PWH who are clinically stable on ART, the choice of dialysis modality should be based on patient preference. All patients on peritoneal dialysis should be instructed in precautions to avoid contamination, and providers should be aware of the potential for infection with atypical organisms in patients with advanced immunosuppression. (See
         <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">
          "Microbiology and therapy of peritonitis in peritoneal dialysis"
         </a>
         .)
        </p>
        <p>
         While retrospective studies from the pre-ART era demonstrated high rates of peritonitis and infections with unusual organisms, limited data are available from the modern ART era. Two small South African studies including patients on peritoneal dialysis taking ART reported conflicting results; in one study, HIV was associated with a higher risk of peritonitis, particularly in patients with CD4 count &lt;200 cells/mm
         <sup>
          3
         </sup>
         , and in the other study, HIV was not identified as an independent risk factor for peritonitis [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2652238836">
         <span class="h1">
          COMPLICATIONS OF END-STAGE KIDNEY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of people living with HIV (PWH) with end-stage kidney disease (ESKD) also involves treatment of common complications of advanced chronic kidney disease (CKD), including anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD).
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia in PWH with ESKD is frequently multifactorial and may result from erythropoietin deficiency, opportunistic infections, and drug-induced myelosuppression, although the last is rare with newer antiretroviral agents [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">
          "Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2385515594">
         <span class="h2">
          Chronic kidney disease-mineral and bone disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         HIV infection and antiretroviral therapy (ART) are associated with loss of bone mineral density, and the commonly used antiretroviral agent
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         has been associated with alterations in parathyroid hormone and other markers of bone mineral metabolism (see
         <a class="medical medical_review" href="/z/d/html/3738.html" rel="external">
          "Bone and calcium disorders in patients with HIV"
         </a>
         ). The impact of the alternative prodrug
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         on bone health has not been evaluated among patients on maintenance hemodialysis. Although there are no contemporary studies specifically evaluating disordered mineral and bone metabolism in PWH with advanced CKD or ESKD, underlying bone disease may complicate the management of CKD-MBD. (See
         <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">
          "Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Patients on dialysis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          ANTIRETROVIRAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of antiretroviral therapy (ART) is the single most important intervention for people living with HIV (PWH), with or without end-stage kidney disease (ESKD). HIV treatment guidelines from the Department of Health and Human Services recommend initiation of ART in all persons diagnosed with HIV infection, regardless of CD4 cell count [
         <a href="#rid44">
          44
         </a>
         ]. A detailed discussion of the use of ART in PWH can be found elsewhere (see
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         ). Consistent with evidence in the nondialysis population with HIV infection, ART provides substantial survival benefits among PWH with ESKD [
         <a href="#rid45">
          45-50
         </a>
         ], as discussed in detail below.
        </p>
        <p>
         Observational data suggest that ART is also beneficial in HIV-associated nephropathy (HIVAN), including cases with dialysis-dependent kidney failure [
         <a href="#rid19">
          19,20
         </a>
         ]. In several case reports, patients with HIVAN and dialysis-dependent kidney failure became dialysis free after initiating ART [
         <a href="#rid19">
          19,20
         </a>
         ]. Repeat kidney biopsy also revealed significant histologic improvement in the cases that underwent repeat biopsy [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         The selection and dosing of antiretroviral drugs in patients with kidney disease are discussed in detail separately. Inappropriate dosing of ART is common in patients on dialysis and may be associated with inadequate virologic control, medication toxicity, and increased mortality [
         <a href="#rid52">
          52,53
         </a>
         ]. A small number of single-tablet regimens are now approved for use in patients on hemodialysis. Long-acting injectable regimens also are approved for use in patients on hemodialysis. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mortality of patients with acquired immune deficiency syndrome (AIDS) treated with dialysis in the 1980s was extremely high, approaching 100 percent at one year [
         <a href="#rid54">
          54
         </a>
         ]. By comparison, subsequent studies have reported improved survival of people living with HIV (PWH) on dialysis after the introduction of effective antiretroviral therapy (ART) [
         <a href="#rid46">
          46-49
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trends in the mortality of over 14,000 individuals with ESKD attributed to HIVAN were assessed in United States Renal Data System (USRDS) data from 1989 to 2011. Compared with those who initiated dialysis between 1989 and 1992, mortality declined by 40 percent among those initiating dialysis in 1999 to 2000, and by 64 percent among those who started dialysis in 2009 to 2011 [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of African-American patients on dialysis from the USRDS, one-year survival increased from 47 percent during 1990 to 1994 to 65 percent during 1995 to 2001 [
         <a href="#rid48">
          48
         </a>
         ]; five-year survival also increased from 13 to 30 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective cohort study from France reported similar survival (approximately 89 percent) among 164 PWH on hemodialysis and 584 patients on hemodialysis without HIV or diabetes [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, a large, single-center cohort study of African-American end-stage kidney disease (ESKD) patients in Baltimore, Maryland failed to demonstrate an improvement in survival with the advent of ART, possibly reflecting inadequate ART in this urban population [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2017 analysis of data from a large United States dialysis provider demonstrated higher mortality among patients with HIV-hepatitis C virus coinfection compared with HIV-negative patients. HIV monoinfection was also associated with higher mortality among Black patients on dialysis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Long-term exposure to ART has been associated with an increased risk of cardiovascular disease in PWH on dialysis [
         <a href="#rid56">
          56
         </a>
         ]. Regimens containing protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs), in particular, have been associated with metabolic abnormalities and endothelial dysfunction, and increasing exposure to specific agents has been associated with an increased risk of myocardial infarction in large cohort studies [
         <a href="#rid57">
          57-61
         </a>
         ]. While the NRTI
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         has received the most attention [
         <a href="#rid58">
          58,59,61
         </a>
         ], pooled data from premarketing clinical trials of abacavir did not demonstrate any excess risk [
         <a href="#rid62">
          62
         </a>
         ], and data from a large, collaborative cohort study have also implicated several other ART agents [
         <a href="#rid60">
          60
         </a>
         ]. The potential for additive cardiovascular risk in patients with ESKD should be balanced against the well-established benefits of ART.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         With improved survival and better long-term prognosis, kidney transplantation has emerged as an important consideration in people living with HIV (PWH) with end-stage kidney disease (ESKD). The potential for significant interactions between calcineurin inhibitors and antiretroviral therapy (ART) requires close communication between the transplant team and HIV providers. Kidney transplantation in PWH is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7332.html" rel="external">
          "Kidney transplantation in adults: Kidney transplantation in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3561413317">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">
          "Society guideline links: Dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – The prevalence of human immunodeficiency virus (HIV) infection in patients on dialysis is difficult to estimate and appears to vary in part based on the local HIV seroprevalence. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV testing
         </strong>
         – We recommend voluntary, confidential HIV testing of all patients on dialysis. Potential benefits of routine screening include improved patient survival, possible reversal of HIV-associated nephropathy (HIVAN), and implementation of measures to prevent transmission to partners. (See
         <a class="local">
          'Human immunodeficiency virus testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transmission of HIV in the dialysis unit
         </strong>
         – HIV transmission in the dialysis setting, which is rare, can be avoided by strict adherence to standard infection-control procedures. In agreement with the Centers for Disease Control and Prevention (CDC), we feel that no special isolation of people living with HIV (PWH) on dialysis is necessary. (See
         <a class="local">
          'Transmission in the dialysis unit'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiretroviral therapy
         </strong>
         – The use of antiretroviral therapy (ART) is the single most important intervention for PWH. ART is associated with the reversal of HIVAN and with decreased mortality in patients on dialysis. However, inappropriate dosing of ART is common in patients on dialysis and may be associated with inadequate virologic control or with medication toxicity. (See
         <a class="local">
          'Antiretroviral therapy'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007; 21:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 2006; 69:1885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasch MG, Helleberg M, Feldt-Rasmussen B, et al. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population. Nephrol Dial Transplant 2014; 29:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jotwani V, Li Y, Grunfeld C, et al. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012; 59:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Althoff KN, McGinnis KA, Wyatt CM, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 2015; 60:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryom L, Mocroft A, Kirk O, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 2014; 28:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryom L, Kirk O, Lundgren JD, et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013; 14:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bickel M, Marben W, Betz C, et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med 2013; 14:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi AI, Rodriguez RA, Bacchetti P, et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007; 18:2968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas GM, Mehta SH, Atta MG, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007; 21:2435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008; 197:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung RKY, Binns-Roemer E, Booth JW, et al. Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV. Kidney Int Rep 2022; 7:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawinski D, Forde KA, Locke JE, et al. Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int 2018; 93:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razzak Chaudhary S, Workeneh BT, Montez-Rath ME, et al. Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant 2015; 30:1734.
          </a>
         </li>
         <li class="breakAll">
          US Preventive Services Task Force. Final Recommendation Statement. Human Immunodeficiency Infection (HIV): Screening, April 2013. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/human-immunodeficiency-virus-hiv-infection-screening (Accessed on March 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterman TA, Lang GR, Mikos NJ, et al. HTLV-III/LAV infection in hemodialysis patients. JAMA 1986; 255:2324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ujhelyi E, Füst G, Illei G, et al. Different types of false positive anti-HIV reactions in patients on haemodialysis. Immunol Lett 1989; 22:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnow PM, Fellner S, Harrington R, Leuther M. False-positive results of screening for antibodies to human immunodeficiency virus in chronic hemodialysis patients. Am J Kidney Dis 1988; 11:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vardinon N, Yust I, Katz O, et al. Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up. Am J Kidney Dis 1999; 34:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou CC, Sun CY, Wu MS. Human immunodeficiency virus (HIV) infection screening in a dialysis unit. Ren Fail 2007; 29:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja TS, O'brien WA. Special issues in the management of patients with ESRD and HIV infection. Am J Kidney Dis 2003; 41:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). HIV transmission in a dialysis center--Colombia, 1991-1993. MMWR Morb Mortal Wkly Rep 1995; 44:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyer E. Argentinian doctors accused of spreading AIDS. BMJ 1993; 307:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velandia M, Fridkin SK, Cárdenas V, et al. Transmission of HIV in dialysis centre. Lancet 1995; 345:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Sayed NM, Gomatos PJ, Beck-Sagué CM, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis 2000; 181:91.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Frequently Asked Questions—Bloodborne Pathogens—Occupational Exposure. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed on March 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja TS, Niaz N, Velasco A, et al. Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Clin Nephrol 1999; 51:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breyer JA, Harbison MA. Isolation of human immunodeficiency virus from peritoneal dialysate. Am J Kidney Dis 1993; 21:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheel PJ Jr, Farzadegan H, Ford D, et al. Recovery of human immunodeficiency virus from peritoneal dialysis effluent. J Am Soc Nephrol 1995; 5:1926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farzadegan H, Ford D, Malan M, et al. HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int 1996; 50:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja TS, Collinge N, Grady J, Khan S. Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy? Am J Kidney Dis 2003; 41:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dicken QG, Cheng TW, Farber A, et al. Patients with human immunodeficiency virus infection do not have inferior outcomes after dialysis access creation. J Vasc Surg 2020; 72:2113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ndlovu KC, Sibanda W, Assounga A. Peritonitis outcomes in patients with HIV and end-stage renal failure on peritoneal dialysis: a prospective cohort study. BMC Nephrol 2017; 18:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sunnyraj MM, Davies M, Cassimjee Z. Peritoneal dialysis outcomes in a tertiary-level state hospital in Johannesburg, South Africa: Ethnicity and HIV co-infection do not increase risk of peritonitis or discontinuation. S Afr Med J 2023; 113:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrivastava D, Rao TK, Sinert R, et al. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis 1995; 25:904.
          </a>
         </li>
         <li class="breakAll">
          Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed on March 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis 2000; 36:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ifudu O, Mayers JD, Matthew JJ, et al. Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: has the outcome changed in the 1990s? Am J Kidney Dis 1997; 29:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002; 13:1889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macrae J, Friedman AL, Eggers P, Friedman EA. Improved survival in HIV-infected African-Americans with ESRD. Clin Nephrol 2005; 64:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourret J, Tostivint I, du Montcel ST, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 2006; 1:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trullàs JC, Cofan F, Barril G, et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr 2011; 57:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramoutar V, Makary R, Ravi M, et al. Liberation from Dialysis Dependence in a Patient with HIV-Associated Nephropathy (HIVAN) after Combined Antiretroviral Therapy (cART). Case Rep Nephrol 2020; 2020:7294765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourret J, Tostivint I, Tézenas Du Montcel S, et al. Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. Clin Infect Dis 2007; 45:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi AI, Rodriguez RA, Bacchetti P, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 2007; 45:1633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortiz C, Meneses R, Jaffe D, et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988; 34:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atta MG, Fine DM, Kirk GD, et al. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis 2007; 45:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberai PC, Dalal D, Zhang L, et al. Incidence of atherosclerotic cardiovascular disease among HIV patients receiving dialysis. Am J Kidney Dis 2006; 47:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160:2050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1915 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17885301" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chronic kidney disease in HIV infection: an urban epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625149" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : HIV-related nephropathy: a South African perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23975841" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22206742" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25362204" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24361680" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23590641" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22994610" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942954" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Racial differences in end-stage renal disease rates in HIV infection versus diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18025880" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18422458" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35497797" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794854" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : MYH9 is associated with nondiabetic end-stage renal disease in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794856" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647424" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association of trypanolytic ApoL1 variants with kidney disease in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29107361" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26175146" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26175146" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9737285" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : HIV-1-associated nephropathy and response to highly-active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11430327" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3007792" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : HTLV-III/LAV infection in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2673997" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Different types of false positive anti-HIV reactions in patients on haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3285669" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : False-positive results of screening for antibodies to human immunodeficiency virus in chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10401029" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17497469" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Human immunodeficiency virus (HIV) infection screening in a dialysis unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552489" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Special issues in the management of patients with ESRD and HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11349873" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Recommendations for preventing transmission of infections among chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7753013" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : HIV transmission in a dialysis center--Colombia, 1991-1993.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8401012" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Argentinian doctors accused of spreading AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7760615" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Transmission of HIV in dialysis centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10608755" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10608755" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9366579" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988145" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8418621" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Isolation of human immunodeficiency virus from peritoneal dialysate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7620089" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recovery of human immunodeficiency virus from peritoneal dialysis effluent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8914033" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : HIV-1 survival kinetics in peritoneal dialysis effluent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12722041" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25234519" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32276018" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Patients with human immunodeficiency virus infection do not have inferior outcomes after dialysis access creation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28158991" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Peritonitis outcomes in patients with HIV and end-stage renal failure on peritoneal dialysis: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36757076" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Peritoneal dialysis outcomes in a tertiary-level state hospital in Johannesburg, South Africa: Ethnicity and HIV co-infection do not increase risk of peritonitis or discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7771487" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7771487" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10977790" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9100043" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: has the outcome changed in the 1990s?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12089385" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16114788" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Improved survival in HIV-infected African-Americans with ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699354" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Outcome and prognosis factors in HIV-infected hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21623213" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32257472" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Liberation from Dialysis Dependence in a Patient with HIV-Associated Nephropathy (HIVAN) after Combined Antiretroviral Therapy (cART).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17712764" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18190326" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3184600" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Outcome of patients with human immunodeficiency virus on maintenance hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18190325" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632024" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Incidence of atherosclerotic cardiovascular disease among HIV patients receiving dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10888979" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753925" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18387667" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20039804" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19682101" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282778" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
